404 related articles for article (PubMed ID: 26873969)
21. Bone morphogenetic protein-2 antagonizes bone morphogenetic protein-4 induced cardiomyocyte hypertrophy and apoptosis.
Lu J; Sun B; Huo R; Wang YC; Yang D; Xing Y; Xiao XL; Xie X; Dong DL
J Cell Physiol; 2014 Oct; 229(10):1503-10. PubMed ID: 24648278
[TBL] [Abstract][Full Text] [Related]
22. Perturbation of hepcidin expression by BMP type I receptor deletion induces iron overload in mice.
Steinbicker AU; Bartnikas TB; Lohmeyer LK; Leyton P; Mayeur C; Kao SM; Pappas AE; Peterson RT; Bloch DB; Yu PB; Fleming MD; Bloch KD
Blood; 2011 Oct; 118(15):4224-30. PubMed ID: 21841161
[TBL] [Abstract][Full Text] [Related]
23. ALK2 functions as a BMP type I receptor and induces Indian hedgehog in chondrocytes during skeletal development.
Zhang D; Schwarz EM; Rosier RN; Zuscik MJ; Puzas JE; O'Keefe RJ
J Bone Miner Res; 2003 Sep; 18(9):1593-604. PubMed ID: 12968668
[TBL] [Abstract][Full Text] [Related]
24. BMP Ligand Trap ALK3-Fc Attenuates Osteogenesis and Heterotopic Ossification in Blast-Related Lower Extremity Trauma.
Strong AL; Spreadborough PJ; Dey D; Yang P; Li S; Lee A; Haskins RM; Grimm PD; Kumar R; Bradley MJ; Yu PB; Levi B; Davis TA
Stem Cells Dev; 2021 Jan; 30(2):91-105. PubMed ID: 33256557
[TBL] [Abstract][Full Text] [Related]
25. Growth differentiation factor-9 signaling is mediated by the type I receptor, activin receptor-like kinase 5.
Mazerbourg S; Klein C; Roh J; Kaivo-Oja N; Mottershead DG; Korchynskyi O; Ritvos O; Hsueh AJ
Mol Endocrinol; 2004 Mar; 18(3):653-65. PubMed ID: 14684852
[TBL] [Abstract][Full Text] [Related]
26. Adiponectin mediates cardioprotection in oxidative stress-induced cardiac myocyte remodeling.
Essick EE; Ouchi N; Wilson RM; Ohashi K; Ghobrial J; Shibata R; Pimentel DR; Sam F
Am J Physiol Heart Circ Physiol; 2011 Sep; 301(3):H984-93. PubMed ID: 21666115
[TBL] [Abstract][Full Text] [Related]
27. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.
van Dinther M; Visser N; de Gorter DJ; Doorn J; Goumans MJ; de Boer J; ten Dijke P
J Bone Miner Res; 2010 Jun; 25(6):1208-15. PubMed ID: 19929436
[TBL] [Abstract][Full Text] [Related]
28. C1QTNF1 attenuates angiotensin II-induced cardiac hypertrophy via activation of the AMPKa pathway.
Wu L; Gao L; Zhang D; Yao R; Huang Z; Du B; Wang Z; Xiao L; Li P; Li Y; Liang C; Zhang Y
Free Radic Biol Med; 2018 Jun; 121():215-230. PubMed ID: 29733904
[TBL] [Abstract][Full Text] [Related]
29. Stachydrine hydrochloride suppresses phenylephrine-induced pathological cardiac hypertrophy by inhibiting the calcineurin/nuclear factor of activated T-cell signalling pathway.
Zheng J; Tian J; Wang S; Hu P; Wu Q; Shan X; Zhao P; Zhang C; Guo W; Xu M; Chen H; Lu R
Eur J Pharmacol; 2020 Sep; 883():173386. PubMed ID: 32712088
[TBL] [Abstract][Full Text] [Related]
30. Aspirin Attenuates Angiotensin II-induced Cardiomyocyte Hypertrophy by Inhibiting the Ca(2+)/Calcineurin-NFAT Signaling Pathway.
Yin Z; Wang X; Zhang L; Zhou H; Wei L; Dong X
Cardiovasc Ther; 2016 Feb; 34(1):21-9. PubMed ID: 26506219
[TBL] [Abstract][Full Text] [Related]
31. Epoxyeicosatrienoic acid prevents maladaptive remodeling in pressure overload by targeting calcineurin/NFAT and Smad-7.
Li X; Chu G; Zhu F; Zheng Z; Wang X; Zhang G; Wang F
Exp Cell Res; 2020 Jan; 386(1):111716. PubMed ID: 31734152
[TBL] [Abstract][Full Text] [Related]
32. Cardiac Hypertrophy Is Inhibited by a Local Pool of cAMP Regulated by Phosphodiesterase 2.
Zoccarato A; Surdo NC; Aronsen JM; Fields LA; Mancuso L; Dodoni G; Stangherlin A; Livie C; Jiang H; Sin YY; Gesellchen F; Terrin A; Baillie GS; Nicklin SA; Graham D; Szabo-Fresnais N; Krall J; Vandeput F; Movsesian M; Furlan L; Corsetti V; Hamilton G; Lefkimmiatis K; Sjaastad I; Zaccolo M
Circ Res; 2015 Sep; 117(8):707-19. PubMed ID: 26243800
[TBL] [Abstract][Full Text] [Related]
33. FGFR3 induces degradation of BMP type I receptor to regulate skeletal development.
Qi H; Jin M; Duan Y; Du X; Zhang Y; Ren F; Wang Y; Tian Q; Wang X; Wang Q; Zhu Y; Xie Y; Liu C; Cao X; Mishina Y; Chen D; Deng CX; Chang Z; Chen L
Biochim Biophys Acta; 2014 Jul; 1843(7):1237-47. PubMed ID: 24657641
[TBL] [Abstract][Full Text] [Related]
34. Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation.
Donaldson C; Eder S; Baker C; Aronovitz MJ; Weiss AD; Hall-Porter M; Wang F; Ackerman A; Karas RH; Molkentin JD; Patten RD
Circ Res; 2009 Jan; 104(2):265-75, 11p following 275. PubMed ID: 19074476
[TBL] [Abstract][Full Text] [Related]
35. Alamandine acts via MrgD to induce AMPK/NO activation against ANG II hypertrophy in cardiomyocytes.
Jesus ICG; Scalzo S; Alves F; Marques K; Rocha-Resende C; Bader M; Santos RAS; Guatimosim S
Am J Physiol Cell Physiol; 2018 Jun; 314(6):C702-C711. PubMed ID: 29443552
[TBL] [Abstract][Full Text] [Related]
36. COX-2 is involved in ET-1-induced hypertrophy of neonatal rat cardiomyocytes: role of NFATc3.
Li H; Gao S; Ye J; Feng X; Cai Y; Liu Z; Lu J; Li Q; Huang X; Chen S; Liu P
Mol Cell Endocrinol; 2014 Feb; 382(2):998-1006. PubMed ID: 24291639
[TBL] [Abstract][Full Text] [Related]
37. Bone morphogenetic protein type I receptor antagonists decrease growth and induce cell death of lung cancer cell lines.
Langenfeld E; Hong CC; Lanke G; Langenfeld J
PLoS One; 2013; 8(4):e61256. PubMed ID: 23593444
[TBL] [Abstract][Full Text] [Related]
38. BMP-2 induces cell migration and periostin expression during atrioventricular valvulogenesis.
Inai K; Norris RA; Hoffman S; Markwald RR; Sugi Y
Dev Biol; 2008 Mar; 315(2):383-96. PubMed ID: 18261719
[TBL] [Abstract][Full Text] [Related]
39. HSF1 phosphorylation by ERK/GSK3 suppresses RNF126 to sustain IGF-IIR expression for hypertension-induced cardiomyocyte hypertrophy.
Huang CY; Lee FL; Peng SF; Lin KH; Chen RJ; Ho TJ; Tsai FJ; Padma VV; Kuo WW; Huang CY
J Cell Physiol; 2018 Feb; 233(2):979-989. PubMed ID: 28383811
[TBL] [Abstract][Full Text] [Related]
40. Activin receptor-like kinase-2 inhibits activin signaling by blocking the binding of activin to its type II receptor.
Renlund N; O'Neill FH; Zhang L; Sidis Y; Teixeira J
J Endocrinol; 2007 Oct; 195(1):95-103. PubMed ID: 17911401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
